TrialESMO open2023

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.

H Yasui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.